HER2+ Breast Cancer

Oleg Gluz, MD, highlights the feasibility of de-escalated neoadjuvant therapy plus trastuzumab and pertuzumab in patients with HR+/HER2+ breast cancer.

Oleg Gluz, MD, discusses data from the WSG-TP-II trial of neoadjuvant endocrine therapy plus trastuzumab and pertuzumab in HR+/HER2+ early breast cancer.

Breast cancer experts highlight early-phase and real-world studies of interest from the 2024 ESMO Congress.

David Rimm, MD, PhD, discusses the limitations of current HER2 immunohistochemistry assays in breast cancer.

Yuan Yuan, MD, PhD, discusses radiation therapy approaches across various of breast cancer subtypes.

Paolo Tarantino, MD, discusses advancements that may lead to more tailored treatment approaches in early-stage HER2+ breast cancer.

Neoadjuvant endocrine therapy or paclitaxel combined with trastuzumab and pertuzumab achieved notable survival benefits in HR-positive, HER2-positive early breast cancer.

Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.

Nancy U. Lin, MD, discusses the DESTINY-Breast12 trial of T-DXd in patients with HER2-positive metastatic breast cancer with or without brain metastases.

T-DXd showcased overall and intracranial activity in patients with HER2-positive metastatic breast cancer with stable and active brain metastases.

As more therapies emerge for HER2-positive, -low, or -negative breast cancer, pathologists highlight the need for more precise methods of evaluating HER2 expression.

HER2DX showed a strong association between ERBB2 mRNA score and survival outcomes in tumor samples from patients with advanced HER2-positive breast cancer.

Pyrotinib paired with metronomic vinorelbine was safe and displayed efficacy in HER2-positive advanced breast cancer after prior trastuzumab.

Sara M. Tolaney, MD, MPH, discusses standard-of-care frontline treatment approaches for patients with HER2-positive breast cancer.

Adjuvant trastuzumab plus concurrent chemotherapy led to inferior DFS outcomes when administered for 9 weeks vs 1 year in ERBB2-positive breast cancer.

Peter Forsyth, MD, discusses the evaluation of intrathecal dendritic cells for patients with TNBC/HER2-positive leptomeningeal disease.

Adrienne G. Waks, MD, discusses efforts to improve treatment outcomes for patients with HER2-positive breast cancer with residual disease.

Barbara Jane O’Brien, MD, discusses tucatinib plus trastuzumab and capecitabine for leptomeningeal metastases in HER2-positive breast cancer.

Rita Nanda, MD, discusses efforts to de-escalate adjuvant therapy for patients with select breast cancers who responded to neoadjuvant therapy.

Sara M. Tolaney, MD, MPH, discusses standard frontline treatment approaches for patients with HER2-positive breast cancer.

The EMA has validated a type II variation application for trastuzumab deruxtecan for select patients with HER2-low or -ultralow metastatic breast cancer.

Adrienne G. Waks, MD, discusses how neoadjuvant and adjuvant anthracycline- and taxane-based regimens compare with one another in HER2+ breast cancer.

Sara M. Tolaney, MD, MPH, discusses the use of ADCs in HER2-positive breast cancer and ongoing research in this patient population.

Sara M. Tolaney, MD, MPH discusses ongoing clinical trials investigating the addition of HER2-directed therapies to existing treatment regimens for HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses the HER2-positive breast cancer treatment paradigm and how standard agents may be optimized to improve outcomes.